“Strongest” is not a complete scientific comparison. A peptide can produce a large change in a hormone measurement without having demonstrated the physical outcome a reader wants.
An early placebo-controlled hexarelin study investigated acute GH release in 12 healthy men. It was a physiological experiment, not a long-term trial of muscle growth, strength or injury recovery. Describing its result as “potent GH release” preserves the endpoint; describing it as proven muscle building does not.
What evidence would close the gap?
A muscle claim needs an actual muscle-related outcome, an appropriate comparison group and enough follow-up to interpret the change. If strength is the goal, body size alone is insufficient. If recovery is the goal, a hormone peak does not describe return to function or healing.
These distinctions matter when several substances appear in a testimonial. Training changes, nutrition, other drugs and expectations can all be part of the story, while the post credits only hexarelin. The account may accurately describe someone's experience without identifying its cause.
The early study also does not rank modern catalog products. The same compound name does not establish that a later vial matches the studied material in identity, formulation or quality.
A useful way to review a claim is to write down its exact verb. “Released,” “increased,” “improved” and “healed” can refer to very different measurements. Then locate that measurement in the paper rather than inferring it from the pathway.
For someone concerned about an endocrine disorder or unexplained loss of function, the appropriate step is clinical assessment, not treating the largest hormone response as the best treatment.
The evidence supports hexarelin's ability to provoke GH release under controlled conditions. It does not establish a general muscle-building prescription, and it provides no basis here for a dose, cycle or performance-enhancement plan.